Fran Beideman and Nick Toltl have been named managers of R&D at SGS Life Science Services. In their new roles, Dr. Beideman and Dr. Toltl will provide strategic technical leadership and resource management for expansion of R&D capabilities at the NJ and Ontario facilities.

The ongoing R&D expansion is part of SGS’ aggressive growth planfor its four U.S. facilities, and follows efforts to enhance biologics testing services through a recent acquisition of M-Scan.

“Dr. Beideman and Dr. Toltl are the ideal people to grow our R&D services,” said Don Castle, senior vice president of SGS Life Sciences North America. “Their extensive experience managing analytical development programs for global life science companies allows us to relate more closely with our clients, and significantly advances the scope of service and expertise we can offer.”

Dr. Beideman has more than 30 years of pharmaceutical industry experience. In his previous role as senior director of analytical development with Pfizer, he led analytical chemistry support for marketed products. His expertise covers method transfers, extractables and leachables and laboratory management.

Prior to joining SGS Life Science Services, Dr. Toltl was with Eli Lilly for 10 years, most recently as a principal research scientist, where he managed development groups and provided technical leadership for global analytical development. He has proven expertise in method development and validation, degradation pathways, stability and setting specifications and has been published on topics including: dissolution, HPLC method development, and mass spectrometry.